Last Updated : May 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
---|---|---|---|---|---|---|
Neulasta | Pegfilgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
Pegasys RBV | Peginterferon alfa-2a and Ribavirin | Hepatitis C, chronic | List in a similar manner to other drugs in class | Complete | ||
Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | ||
Iressa | Gefitinib | Cancer, Lung , non-small cell | Do not list | Complete | ||
Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | ||
Combigan Ophthalmic Solution | Brimonidine tartrate/timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
Reyataz | Atazanavir | HIV infection | List in a similar manner to other drugs in class | Complete | ||
Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn |